Published in J Virol on June 01, 2004
Vaccinia virus proteome: identification of proteins in vaccinia virus intracellular mature virion particles. J Virol (2006) 2.38
Entry of vaccinia virus and cell-cell fusion require a highly conserved cysteine-rich membrane protein encoded by the A16L gene. J Virol (2006) 1.63
Vaccinia virus l1 protein is required for cell entry and membrane fusion. J Virol (2008) 1.39
Vaccinia virus nonstructural protein encoded by the A11R gene is required for formation of the virion membrane. J Virol (2005) 1.39
Characterization of a newly identified 35-amino-acid component of the vaccinia virus entry/fusion complex conserved in all chordopoxviruses. J Virol (2009) 1.16
Assembly and disassembly of the capsid-like external scaffold of immature virions during vaccinia virus morphogenesis. J Virol (2009) 1.14
Vaccinia virus H7 protein contributes to the formation of crescent membrane precursors of immature virions. J Virol (2009) 1.04
The vaccinia virus F13L YPPL motif is required for efficient release of extracellular enveloped virus. J Virol (2007) 1.02
Vaccinia virus mutants with alanine substitutions in the conserved G5R gene fail to initiate morphogenesis at the nonpermissive temperature. J Virol (2004) 1.02
A conditional-lethal vaccinia virus mutant demonstrates that the I7L gene product is required for virion morphogenesis. Virol J (2005) 1.01
Participation of vaccinia virus l2 protein in the formation of crescent membranes and immature virions. J Virol (2011) 1.00
Vaccinia virus G1 protein, a predicted metalloprotease, is essential for morphogenesis of infectious virions but not for cleavage of major core proteins. J Virol (2004) 1.00
Identification of novel antipoxviral agents: mitoxantrone inhibits vaccinia virus replication by blocking virion assembly. J Virol (2007) 1.00
Poxvirus proteomics and virus-host protein interactions. Microbiol Mol Biol Rev (2009) 0.98
Vaccinia virus virion membrane biogenesis protein A11 associates with viral membranes in a manner that requires the expression of another membrane biogenesis protein, A6. J Virol (2012) 0.91
Poxvirus membrane biogenesis. Virology (2015) 0.89
A lead discovery strategy driven by a comprehensive analysis of proteases in the peptide substrate space. Protein Sci (2010) 0.88
Lipid membranes in poxvirus replication. Viruses (2010) 0.88
Cidofovir inhibits genome encapsidation and affects morphogenesis during the replication of vaccinia virus. J Virol (2009) 0.87
Poxvirus membrane biogenesis: rupture not disruption. Cell Microbiol (2012) 0.87
Discovery of small molecule inhibitors of ubiquitin-like poxvirus proteinase I7L using homology modeling and covalent docking approaches. J Comput Aided Mol Des (2007) 0.82
Development of an in vitro cleavage assay system to examine vaccinia virus I7L cysteine proteinase activity. Virol J (2005) 0.82
The E6 protein from vaccinia virus is required for the formation of immature virions. Virology (2010) 0.81
Regulation of a viral proteinase by a peptide and DNA in one-dimensional space: III. atomic resolution structure of the nascent form of the adenovirus proteinase. J Biol Chem (2012) 0.81
Interactions of the vaccinia virus A19 protein. J Virol (2013) 0.81
From crescent to mature virion: vaccinia virus assembly and maturation. Viruses (2014) 0.81
Genetic Confirmation that the H5 Protein Is Required for Vaccinia Virus DNA Replication. J Virol (2015) 0.80
Analysis of vaccinia virus temperature-sensitive I7L mutants reveals two potential functional domains. Virol J (2006) 0.80
Vaccinia virus mutations in the L4R gene encoding a virion structural protein produce abnormal mature particles lacking a nucleocapsid. J Virol (2014) 0.80
Duplication of the A17L locus of vaccinia virus provides an alternate route to rifampin resistance. J Virol (2014) 0.80
Characterization of vaccinia virus A12L protein proteolysis and its participation in virus assembly. Virol J (2007) 0.79
Expression of the highly conserved vaccinia virus E6 protein is required for virion morphogenesis. Virology (2009) 0.79
Characterization of a large, proteolytically processed cowpox virus membrane glycoprotein conserved in most chordopoxviruses. Virology (2015) 0.79
Vaccinia virus A19 protein participates in the transformation of spherical immature particles to barrel-shaped infectious virions. J Virol (2013) 0.79
Vaccinia virus protein A3 is required for the production of normal immature virions and for the encapsidation of the nucleocapsid protein L4. Virology (2015) 0.78
Functional characterization of the vaccinia virus I5 protein. Virol J (2008) 0.78
Incomplete but infectious vaccinia virions are produced in the absence of oncolysis in feline SCCF1 cells. PLoS One (2015) 0.77
Activity, specificity, and probe design for the smallpox virus protease K7L. J Biol Chem (2012) 0.77
Cleavage of Dicer protein by I7 protease during vaccinia virus infection. PLoS One (2015) 0.77
Protein Primary Structure of the Vaccinia Virion at Increased Resolution J Virol (2016) 0.76
Vaccinia Virus B1 Kinase Is Required for Postreplicative Stages of the Viral Life Cycle in a BAF-Independent Manner in U2OS Cells. J Virol (2015) 0.75
The vaccinia virus E6 protein influences virion protein localization during virus assembly. Virology (2015) 0.75
A new protease required for cell-cycle progression in yeast. Nature (1999) 5.44
The development of vaccinia virus in Earle's L strain cells as examined by electron microscopy. J Biophys Biochem Cytol (1961) 4.32
Rifampicin: a specific inhibitor of vaccinia virus assembly. Nature (1969) 3.74
Formation of a vaccinia virus structural polypeptide from a higher molecular weight precursor: inhibition by rifampicin. Proc Natl Acad Sci U S A (1970) 3.50
Isolation, characterization, and physical mapping of temperature-sensitive mutants of vaccinia virus. Virology (1983) 3.33
Vaccinia virus A17L open reading frame encodes an essential component of nascent viral membranes that is required to initiate morphogenesis. J Virol (1996) 2.77
Letter: Protein cleavage and poxvirus morphogenesis: tryptic peptide analysis of core precursors accumulated by blocking assembly with rifampicin. J Mol Biol (1973) 2.47
Stringent chemical and thermal regulation of recombinant gene expression by vaccinia virus vectors in mammalian cells. Proc Natl Acad Sci U S A (1995) 2.45
The adenovirus protease is activated by a virus-coded disulphide-linked peptide. Cell (1993) 1.86
The multistep proteolytic maturation pathway utilized by vaccinia virus P4a protein: a degenerate conserved cleavage motif within core proteins. Virology (1991) 1.86
The vaccinia virus 14-kilodalton fusion protein forms a stable complex with the processed protein encoded by the vaccinia virus A17L gene. J Virol (1993) 1.86
Regulation of vaccinia virus morphogenesis: phosphorylation of the A14L and A17L membrane proteins and C-terminal truncation of the A17L protein are dependent on the F10L kinase. J Virol (1999) 1.78
N-terminal amino acid sequences of vaccinia virus structural proteins. Virology (1994) 1.71
Proteolytic maturation of vaccinia virus core proteins: identification of a conserved motif at the N termini of the 4b and 25K virion proteins. J Gen Virol (1991) 1.70
Vaccinia virus morphogenesis is blocked by a temperature-sensitive mutation in the I7 gene that encodes a virion component. J Virol (1993) 1.68
Characterization of ts 16, a temperature-sensitive mutant of vaccinia virus. J Virol (1995) 1.66
The vaccinia virus I7L gene product is the core protein proteinase. J Virol (2002) 1.61
African swine fever virus protease, a new viral member of the SUMO-1-specific protease family. J Biol Chem (2001) 1.60
New vaccinia virus recombination plasmids incorporating a synthetic late promoter for high level expression of foreign proteins. Nucleic Acids Res (1990) 1.58
Differential utilization of a conserved motif for the proteolytic maturation of vaccinia virus proteins. Virology (1994) 1.44
Use of a bacterial expression vector to identify the gene encoding a major core protein of vaccinia virus. J Virol (1985) 1.27
Molecular dissection of the vaccinia virus I7L core protein proteinase. J Virol (2003) 1.20
A transcriptionally controlled trans-processing assay: putative identification of a vaccinia virus-encoded proteinase which cleaves precursor protein P25K. J Virol (1994) 1.17
Physical and functional interactions between vaccinia virus F10 protein kinase and virion assembly proteins A30 and G7. J Virol (2004) 1.08
trans processing of vaccinia virus core proteins. J Virol (1993) 1.06
Genetic and molecular biological characterization of a vaccinia virus temperature-sensitive complementation group affecting a virion component. Virology (1991) 1.03
Vaccinia virus G1 protein, a predicted metalloprotease, is essential for morphogenesis of infectious virions but not for cleavage of major core proteins. J Virol (2004) 1.00
Polyprotein processing protease of African swine fever virus: purification and biochemical characterization. J Virol (2003) 0.87
A role for tumor necrosis factor receptor-2 and receptor-interacting protein in programmed necrosis and antiviral responses. J Biol Chem (2003) 3.70
Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature (2004) 3.65
Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. Proc Natl Acad Sci U S A (2003) 3.18
Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge. Proc Natl Acad Sci U S A (2004) 3.08
Colocalization of transcription and translation within cytoplasmic poxvirus factories coordinates viral expression and subjugates host functions. Cell Host Microbe (2007) 2.97
Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys. Cell (2013) 2.88
Overcoming immunity to a viral vaccine by DNA priming before vector boosting. J Virol (2003) 2.67
Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc Natl Acad Sci U S A (2004) 2.38
Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions. J Virol (2004) 2.21
Complete pathway for protein disulfide bond formation encoded by poxviruses. Proc Natl Acad Sci U S A (2002) 2.19
Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine. J Virol (2002) 2.13
Poxvirus multiprotein entry-fusion complex. Proc Natl Acad Sci U S A (2005) 2.09
Vaccinia virus entry into cells is dependent on a virion surface protein encoded by the A28L gene. J Virol (2004) 2.06
Vaccinia virus entry into cells via a low-pH-dependent endosomal pathway. J Virol (2006) 1.94
Protein composition of the vaccinia virus mature virion. Virology (2006) 1.93
Vaccinia virus H2 protein is an essential component of a complex involved in virus entry and cell-cell fusion. J Virol (2005) 1.88
Vaccinia virus A21 virion membrane protein is required for cell entry and fusion. J Virol (2005) 1.86
HIV-1 DNA/MVA vaccination reduces the per exposure probability of infection during repeated mucosal SHIV challenges. Virology (2006) 1.83
Antibody profiling by proteome microarray reveals the immunogenicity of the attenuated smallpox vaccine modified vaccinia virus ankara is comparable to that of Dryvax. J Virol (2007) 1.77
Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. J Infect Dis (2008) 1.77
Discovery of antivirals against smallpox. Proc Natl Acad Sci U S A (2004) 1.76
Prevention of infection by a granulocyte-macrophage colony-stimulating factor co-expressing DNA/modified vaccinia Ankara simian immunodeficiency virus vaccine. J Infect Dis (2011) 1.76
The product of the vaccinia virus L5R gene is a fourth membrane protein encoded by all poxviruses that is required for cell entry and cell-cell fusion. J Virol (2005) 1.73
Development and use of a vaccinia virus neutralization assay based on flow cytometric detection of green fluorescent protein. J Virol (2003) 1.73
Simultaneous high-resolution analysis of vaccinia virus and host cell transcriptomes by deep RNA sequencing. Proc Natl Acad Sci U S A (2010) 1.72
Oligomeric structure of the human immunodeficiency virus type 1 envelope protein on the virion surface. J Virol (2002) 1.69
Attenuated poxvirus-based simian immunodeficiency virus (SIV) vaccines given in infancy partially protect infant and juvenile macaques against repeated oral challenge with virulent SIV. J Acquir Immune Defic Syndr (2005) 1.68
Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. J Infect Dis (2011) 1.67
Entry of vaccinia virus and cell-cell fusion require a highly conserved cysteine-rich membrane protein encoded by the A16L gene. J Virol (2006) 1.63
Vaccinia virus A28L gene encodes an essential protein component of the virion membrane with intramolecular disulfide bonds formed by the viral cytoplasmic redox pathway. J Virol (2004) 1.62
Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol. J Virol (2004) 1.58
External scaffold of spherical immature poxvirus particles is made of protein trimers, forming a honeycomb lattice. J Cell Biol (2005) 1.55
Immunization of newborn rhesus macaques with simian immunodeficiency virus (SIV) vaccines prolongs survival after oral challenge with virulent SIVmac251. J Virol (2003) 1.53
GM-CSF DNA: an adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89.6P challenge by a DNA/MVA immunodeficiency virus vaccine. Virology (2007) 1.52
Physical and immunological characterization of a recombinant secreted form of the membrane protein encoded by the vaccinia virus L1R gene. Virology (2005) 1.49
Vaccinia virus F9 virion membrane protein is required for entry but not virus assembly, in contrast to the related L1 protein. J Virol (2006) 1.45
Epitope-mapping studies define two major neutralization sites on the vaccinia virus extracellular enveloped virus glycoprotein B5R. J Virol (2005) 1.44
Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model. Virology (2002) 1.44
Chimpanzee/human mAbs to vaccinia virus B5 protein neutralize vaccinia and smallpox viruses and protect mice against vaccinia virus. Proc Natl Acad Sci U S A (2006) 1.44
Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate. PLoS One (2010) 1.41
Vaccinia virus G9 protein is an essential component of the poxvirus entry-fusion complex. J Virol (2006) 1.40
Association of vaccinia virus fusion regulatory proteins with the multicomponent entry/fusion complex. J Virol (2007) 1.40
Vaccinia virus G7L protein Interacts with the A30L protein and is required for association of viral membranes with dense viroplasm to form immature virions. J Virol (2003) 1.39
Vaccinia virus l1 protein is required for cell entry and membrane fusion. J Virol (2008) 1.39
Vaccinia virus nonstructural protein encoded by the A11R gene is required for formation of the virion membrane. J Virol (2005) 1.39
Vaccinia virus D10 protein has mRNA decapping activity, providing a mechanism for control of host and viral gene expression. Proc Natl Acad Sci U S A (2007) 1.38
The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2. Cancer Res (2005) 1.34
Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus. Proc Natl Acad Sci U S A (2008) 1.31
Adjuvanting a DNA vaccine with a TLR9 ligand plus Flt3 ligand results in enhanced cellular immunity against the simian immunodeficiency virus. J Exp Med (2007) 1.30
Poxvirus DNA topoisomerase knockout mutant exhibits decreased infectivity associated with reduced early transcription. Proc Natl Acad Sci U S A (2003) 1.28
DNA/MVA vaccine for HIV type 1: effects of codon-optimization and the expression of aggregates or virus-like particles on the immunogenicity of the DNA prime. AIDS Res Hum Retroviruses (2004) 1.27
Preclinical studies of human immunodeficiency virus/AIDS vaccines: inverse correlation between avidity of anti-Env antibodies and peak postchallenge viremia. J Virol (2009) 1.27
Vaccinia virus strain differences in cell attachment and entry. Virology (2009) 1.26
The 1.51-Angstrom structure of the poxvirus L1 protein, a target of potent neutralizing antibodies. Proc Natl Acad Sci U S A (2005) 1.24
Cloning the vaccinia virus genome as a bacterial artificial chromosome in Escherichia coli and recovery of infectious virus in mammalian cells. Proc Natl Acad Sci U S A (2002) 1.24
Design and evaluation of multi-gene, multi-clade HIV-1 MVA vaccines. Vaccine (2009) 1.24
SIVmac239 MVA vaccine with and without a DNA prime, similar prevention of infection by a repeated dose SIVsmE660 challenge despite different immune responses. Vaccine (2011) 1.23
Existence of an operative pathway from the endoplasmic reticulum to the immature poxvirus membrane. Proc Natl Acad Sci U S A (2006) 1.23
Characterization of a second vaccinia virus mRNA-decapping enzyme conserved in poxviruses. J Virol (2007) 1.22
Characterization of a vaccinia virus mutant with a deletion of the D10R gene encoding a putative negative regulator of gene expression. J Virol (2006) 1.22
Inhibition of the ubiquitin-proteasome system prevents vaccinia virus DNA replication and expression of intermediate and late genes. J Virol (2009) 1.22
Synergistic neutralizing activities of antibodies to outer membrane proteins of the two infectious forms of vaccinia virus in the presence of complement. Virology (2004) 1.21
Mapping interaction sites of the A20R protein component of the vaccinia virus DNA replication complex. Virology (2002) 1.21
Adjuvant-enhanced antibody responses to recombinant proteins correlates with protection of mice and monkeys to orthopoxvirus challenges. Vaccine (2007) 1.21
Multiprotein HIV type 1 clade B DNA/MVA vaccine: construction, safety, and immunogenicity in Macaques. AIDS Res Hum Retroviruses (2004) 1.20
Expression profiling of the intermediate and late stages of poxvirus replication. J Virol (2011) 1.20
Genome-wide analysis of the 5' and 3' ends of vaccinia virus early mRNAs delineates regulatory sequences of annotated and anomalous transcripts. J Virol (2011) 1.19
Characterization of chimpanzee/human monoclonal antibodies to vaccinia virus A33 glycoprotein and its variola virus homolog in vitro and in a vaccinia virus mouse protection model. J Virol (2007) 1.19
Similarities in the induction of post-Golgi vesicles by the vaccinia virus F13L protein and phospholipase D. J Virol (2002) 1.18
Characterization of a newly identified 35-amino-acid component of the vaccinia virus entry/fusion complex conserved in all chordopoxviruses. J Virol (2009) 1.16
Enhanced cell surface expression, immunogenicity and genetic stability resulting from a spontaneous truncation of HIV Env expressed by a recombinant MVA. Virology (2007) 1.16
Identification of second-site mutations that enhance release and spread of vaccinia virus. J Virol (2002) 1.16
Degradation of host microRNAs by poxvirus poly(A) polymerase reveals terminal RNA methylation as a protective antiviral mechanism. Cell Host Microbe (2012) 1.15
Modeling a safer smallpox vaccination regimen, for human immunodeficiency virus type 1-infected patients, in immunocompromised macaques. J Infect Dis (2003) 1.15
Appraising the apoptotic mimicry model and the role of phospholipids for poxvirus entry. Proc Natl Acad Sci U S A (2009) 1.15
Vaccinia virus G4L glutaredoxin is an essential intermediate of a cytoplasmic disulfide bond pathway required for virion assembly. J Virol (2002) 1.14
Assembly and disassembly of the capsid-like external scaffold of immature virions during vaccinia virus morphogenesis. J Virol (2009) 1.14
Poxvirus DNA primase. Proc Natl Acad Sci U S A (2007) 1.14
Evidence for an essential catalytic role of the F10 protein kinase in vaccinia virus morphogenesis. J Virol (2004) 1.13
Two distinct low-pH steps promote entry of vaccinia virus. J Virol (2007) 1.13
Identification of wild-derived inbred mouse strains highly susceptible to monkeypox virus infection for use as small animal models. J Virol (2010) 1.13
Studies on GM-CSF DNA as an adjuvant for neutralizing Ab elicited by a DNA/MVA immunodeficiency virus vaccine. Virology (2006) 1.12
Vaccinia virus A36R membrane protein provides a direct link between intracellular enveloped virions and the microtubule motor kinesin. J Virol (2004) 1.12
Immunity from smallpox vaccine persists for decades: a longitudinal study. Am J Med (2008) 1.11
A conserved poxvirus NlpC/P60 superfamily protein contributes to vaccinia virus virulence in mice but not to replication in cell culture. Virology (2008) 1.10
DNA/MVA HIV-1/AIDS vaccine elicits long-lived vaccinia virus-specific immunity and confers protection against a lethal monkeypox challenge. Virology (2007) 1.09
Physical and functional interactions between vaccinia virus F10 protein kinase and virion assembly proteins A30 and G7. J Virol (2004) 1.08
A complex of seven vaccinia virus proteins conserved in all chordopoxviruses is required for the association of membranes and viroplasm to form immature virions. Virology (2004) 1.08
Expression of the A56 and K2 proteins is sufficient to inhibit vaccinia virus entry and cell fusion. J Virol (2008) 1.07
Preexisting vaccinia virus immunity decreases SIV-specific cellular immunity but does not diminish humoral immunity and efficacy of a DNA/MVA vaccine. J Immunol (2010) 1.07
Immunogenicity in macaques of the clinical product for a clade B DNA/MVA HIV vaccine: elicitation of IFN-gamma, IL-2, and TNF-alpha coproducing CD4 and CD8 T cells. AIDS Res Hum Retroviruses (2007) 1.07